Title : Combination approaches to attenuate hemorrhagic transformation after tPA thrombolytic therapy in patients with poststroke hyperglycemia/diabetes.

Pub. Date : 2014

PMID : 25307224






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 To date, tissue type plasminogen activator (tPA)-based thrombolytic stroke therapy is the only FDA-approved treatment for achieving vascular reperfusion and clinical benefit, but this agent is given to only about 5% of stroke patients in the USA. Tetradecanoylphorbol Acetate plasminogen activator, tissue type Homo sapiens